NCT05970978CompletedPhase 2
A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112
Source: ClinicalTrials.gov · Last updated 27 Apr 2025
Brief summary (registry, in English)
This is a multicenter, open-label study aim to evaluate the efficacy and safety of IBI112 in Chinese participants with plaque psoriasis who were treated with biologics and switched to IBI112. The study will enroll 160 participants who were diagnosed with plaque psoriasis. The whole study consists of 4 weeks of screening, 32 or 36 weeks of treatment and a safety follow-up visit at Week 44.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- First submitted
- 24 Jul 2023
- Start date
- 28 Aug 2023
- Primary completion date
- 19 Jul 2024
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Diseases
- Psoriasis
- NCT number
- NCT05970978
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 152
- From 28 Aug 2023 to the primary completion date, 19 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously treated with IBI112 or other IL-23 inhibitors;
- Treated with two biologics for psoriasis within 4 months prior to screening;
- Treated with topical therapy for psoriasis within 2 weeks prior to the first dose administration, or treated with systemic non-biological agents or phototherapy within 4 weeks prior to the first dose administration;
- Treated with Natalizumab, or B/T cell regulators (e.g., Rituximab, Abatacept, or Visilizumab) within 12 months prior to the first dose administration;
- Treated with an investigational biologic within 6 months prior to the first dose administration, or any investigational therapy within 30 days, or an investigational drug within 5 half-lives, or currently participating in a clinical study.
Lab values
- Diagnosed with guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, or drug-induced psoriasis (e.g., psoriasis caused by beta blockers, calcium channel inhibitors, etc.) at screening;
Other
- Not willing to avoid constant sunshine and other ultraviolet light sources exposure during the study;
Who the study is looking for
- 18 to 75 years old;
- Evaluated suitable for continuing biologic therapy for plaque psoriasis by the investigator;
- Received previous biologic therapy with at least 4 months.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology) Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.